Scientific Session
Fibrosing rheumatic diseases (scleroderma, MCTD, IgG4-related disease, scleroderma mimics)
Jörg Distler, MD
University Hospital Duesseldorf and HHU
Duesseldorf, Germany
Disclosure(s): 4D Science: Royalties (Ongoing); AbbVie: Consultant (Ongoing); Anamar: Consultant (Ongoing), Grant/Research Support (Ongoing); Argenx: Grant/Research Support (Ongoing); ARXX: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Boehringer Ingelheim: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Cantargia: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); CSL Behring: Grant/Research Support (Ongoing); FibroCure: Ownership Interest (Ongoing); Genentech/Roche: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Lassen: Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); RedX: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)